TITLE:
A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer
AUTHORS:
Tetsu Yamamoto, Ryoji Hyakudomi, Shinichi Sugimoto, Atsuo Tokuka, Yoshitoshi Sato, Satoshi Nagai, Hikota Hayashi, Masahikoo Igarashi, Kenji Takubo, Yoshitsugu Tajima
KEYWORDS:
Colorectal Cancer, Oxaliplatin, Capecitabine, Bevacizumab, Elderly Patients
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.2,
February
4,
2015
ABSTRACT: Oxaliplatin-based chemotherapy with
bevacizumab is now widely used for colorectal cancer patients. This study
evaluated the efficacy and tolerability of XELOX (capecitabine + oxaliplatin +
leucovorin combined) therapy with or without bevacizumab in elderly patients.
One hundred and seven patients, consisting of 52 elderly (>70 years of age)
and 55 non-elderly, with unresectable colorectal cancer were enrolled in this
multicenter cooperative group study using a database between October 2009 and
March 2012. We evaluated the outcomes in terms of the median time to treat
failure (TTF), overall response rate (ORR), disease control rate (DCR) and
tolerability in both age groups. The median TTF for the XELOX + bevacizumab
regimen was 7.1 months in the non-elderly group and 8.1 months in the elderly
group (p = 0.838). There was no significant difference in TTF between the two
groups. The ORR and DCR in the non-elderly group were 30.8% and 73.1%,
respectively. In the elderly group, the ORR was 40.0% and the overall DCR was
90.0%. No severe or uncontrollable adverse events were observed in the two
groups. These data indicated that the XELOX chemotherapy with or without
bevacizumab has an equivalent efficacy in both groups, without increasing the
adverse events even in the elderly population.